SAN DIEGO, Sept. 27, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it presented positive findings from a Phase I clinical study of MN-029, its novel vascular disrupting agent (VDA), at the 14th European Cancer Conference (ECCO 14) in Barcelona, Spain.
